Why Regeneron Stock Is Falling Today
Portfolio Pulse from Ryan Gustafson
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler. No issues were identified with the drug's clinical efficacy or safety, and no additional clinical data or trials have been requested. The company is committed to working with the FDA and the third-party filler to bring the drug to patients as quickly as possible.

June 27, 2023 | 7:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron's stock price fell due to the FDA's ongoing review of inspection findings at a third-party filler for its aflibercept 8 mg Biologics License application.
The FDA's ongoing review of inspection findings at a third-party filler for Regeneron's aflibercept 8 mg Biologics License application has caused uncertainty among investors, leading to a drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100